### Edgar Filing: Neylan John F. - Form 4

Form 4	F.										
May 01, 2018	3										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								OMB APPROVAL			
-	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287		
Check this if no long							Expires:	January 31, 2005			
subject to Section 10 Form 4 or	subject to Section 16. SECURITIES Form 4 or						NERSHIP OF	Estimated average burden hours per response			
Form 5 obligation may conti <i>See</i> Instru 1(b).	nue. Section	17(a) of the		ility Hold	ing Com	ipany	Act of	ge Act of 1934, f 1935 or Sectio 40	n		
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> Neylan John F.			2. Issuer Name <b>and</b> Ticker or Trading Symbol KERYX				Ig	5. Relationship of Reporting Person(s) to Issuer			
				ARMACE	UTICA	LS IN	NC	(Chec	k all applicable	e) • Owner	
C/O KERYX			<ul><li>3. Date of Earliest Transaction</li><li>(Month/Day/Year)</li><li>04/30/2018</li></ul>					X Officer (give title Other (specify below) below) Chief Medical Officer			
	IACEUTICA MARINA PA TH FLOOR										
			ndment, Date Original th/Day/Year)				<ul><li>6. Individual or Joint/Group Filing(Check</li><li>Applicable Line)</li><li>_X_ Form filed by One Reporting Person</li></ul>				
BOSTON, M	IA 02210							Form filed by M Person	Iore than One Re	porting	
(City)	(State)	(Zip)	Table	e I - Non-Do	erivative S	Securi	ties Acc	quired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution I any (Month/Day		emed on Date, if	Date, if Transaction(A) or Disposed of Code (D) y/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)		Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Comm				Code V	Amount	or (D)	Price \$	(Instr. 3 and 4)			
Common Stock	04/30/2018			S	1,311	D	4.67 (1)	154,314 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

### Edgar Filing: Neylan John F. - Form 4

#### number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amo Unde Secur	tle and unt of vrlying rities : 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Reporting Owners											
	Reporting O	wner Name / Addres	s		Re	elationships					

Director 10% Owner Officer Neylan John F. C/O KERYX BIOPHARMACEUTICALS, INC. **ONE MARINA PARK DRIVE, 12TH FLOOR** BOSTON, MA 02210

Date

## Signatures

/s/ Scott Holmes,	05/01/2018
Attorney-in-Fact	03/01/2018

\*\*Signature of Reporting Person

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Sale of a total of 1,311 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the (1) vesting of 4,479 shares of restricted stock on April 27, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

(2) Includes 87,186 shares of restricted stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Chief Medical Officer

Other